CatalystFDA/Bio

Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

First patient dosed in Phase 3 setidegrasib trial for KRAS G12D-mutated advanced NSCLC.

What changed

First patient dosed in Phase 3 setidegrasib trial for KRAS G12D-mutated advanced NSCLC.

Why it matters

First patient dosed in Phase 3 setidegrasib trial for KRAS G12D-mutated advanced NSCLC. — impact context not separately stored; see What changed.

Sources